# US 2018/0022707 A1 · Therapeutic compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022707 A1
- Document ID: US20180022707A1
- Status: Published application
- Kind: A1
- Application number: 15/643,805
- Filed: 2017-07-07
- Published: 2018-01-25
- Earliest claimed: 2015-01-09
- Assignees: Genentech, Inc.; Constellation Pharmaceuticals, Inc.
- Applicants: Genentech, Inc.; Constellation Pharmaceuticals, Inc.
- Inventors: Brian K. Albrecht; Alexandre Cote; Victor Gehling; Vickie Hsiao-Wei Tsui; James Richard Jr. Kiefer; Jun Liang; Steven Magnuson; Christopher G. Nasveschuk; F. Anthony Romero; Alexander M. Taylor
- Web page: https://patentgrep.com/patent/US20180022707A1

## CPC

- C07D 233/44: Nitrogen atoms not forming part of a nitro radical
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/4995: Pyrazines or piperazines forming part of bridged ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 35/00: Antineoplastic agents
- C07D 235/02: condensed with carbocyclic rings or ring systems
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 487/08: Bridged systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds useful as inhibitors of one or more histone demethylses, such as KDM2b. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.

## Claims

### Claim 1

A compound of formula (I):
or a salt thereof, wherein:
X is C(═O) or S(O)2;
R1 is selected from the group consisting of N-linked piperazinyl, N-linked piperidine, and N-linked diazabicyclo[3.2.1]octane, wherein R1 is optionally substituted with one or more groups independently selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, aryl, 3-10 membered heterocycle, and C3-8cycloalkyl, wherein any aryl, 3-10 membered heterocycle, and C3-8cycloalkyl is optionally substituted with one or more groups independently selected from halo, C1-4alkyl, C2-4alkenyl, and C2-4alkynyl, and wherein any C1-6alkyl, C2-6alkenyl, and C2-6alkynyl is optionally substituted with one or more groups independently selected from halo, C1-4alkoxy, and C3-8cycloalkyl that is optionally substituted with C1-6alkyl;
R2 and R3 are each independently selected from H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, and C3-8cycloalkyl, wherein any C1-6alkyl, C2-6alkenyl, C2-6alkynyl, and C3-8cycloalkyl is optionally substituted with one or more groups independently selected from halo and oxo; or R2 and R3 taken together with the carbon to which they are attached form a 3-, 4-, 5-, or 6-membered carbocyclic ring that is optionally substituted with one or more groups independently selected from halo, oxo, C1-4alkyl, C2-4alkenyl, and C2-4alkynyl;
R4 and R5 are each independently selected from H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, and C3-8cycloalkyl, wherein any C1-6alkyl, C2-6alkenyl, C2-6alkynyl, and C3-8cycloalkyl is optionally substituted with one or more groups independently selected from halo and oxo; or R4 and R5 taken together with the carbon to which they are attached form a 3-, 4-, 5-, or 6-membered carbocyclic ring that is optionally substituted with one or more groups independently selected from halo, oxo, C1-4alkyl, C2-4alkenyl, and C2-4alkynyl;
R6 is a 5-10 membered heteroaryl, 5-10 membered heterocycle, or a 6-10 membered aryl, which 5-10 membered heteroaryl, 5-10 membered heterocycle, and 6-10 membered aryl is optionally substituted with one or more groups independently selected from the group consisting of C1-6alkyl, C2-6alkenyl, C2-6alkynyl, carbocycle, heterocycle, aryl, heteroaryl, halo, —NO2, —N(Rb)2, —CN, —C(O)—N(Rb)2, —S(O)—N(Rb)2, —S(O)2—N(Rb)2, —O—Rb, —S—Rb, —O—C(O)—Rb, —C(O)—Rb, —C(O)—ORb, —S(O)—Rb, —S(O)2—Rb, —N(Rb)—C(O)—Rb, —N(Rb)—S(O)—Rb, —N(Rb)—C(O)—N(Rb)2, and —N(Rb)—S(O)2—Rb; wherein each C1-6alkyl, C2-6alkenyl, C2-6alkynyl, carbocycle, heterocycle, aryl, and heteroaryl is optionally substituted with one or more groups independently selected from the group consisting of halo, —NO2—N(Rb)2, —CN, —C(O)—N(Rb)2, —S(O)—N(Rb)2, —S(O)2—N(Rb)2, —O—Rb, —S—Rb, —O—C(O)—Rb, —C(O)—Rb, —C(O)—ORb, —S(O)—Rb, —S(O)2—Rb, —N(Rb)—C(O)—Rb, —N(Rb)—S(O)—Rb, —N(Rb)—C(O)—N(Rb)2, —N(Rb)—S(O)2—Rb, and C1-6alkyl that is optionally substituted with one or more groups independently selected from halo;
each Rb is independently selected from the group consisting of hydrogen, C1-6alkyl, C2-6alkenyl, aryl, and C2-6alkynyl, wherein each C1-6alkyl, C2-6alkenyl, aryl, and C2-6alkynyl is optionally substituted with one or more groups independently selected from the group consisting of halo, —N(Rc)2, —CN, —C(O)—N(Rc)2, —S(O)—N(Rc)2, —S(O)2—N(Rc)2, —S—Rc, —O—C(O)—Rc, —C(O)—Rc, —C(O)—ORc, —S(O)—Rc, —S(O)2—Rc, —N(Rc)—C(O)—Rc, —N(Rc)—S(O)—Rc, —N(Rc)—C(O)—N(Rc)2, and —N(Rc)—S(O)2—Rc; or two Rb are taken together with the nitrogen to which they are attached to form a pyrrolidino, piperidino, or piperazino ring; and
each Rc is independently selected from the group consisting of hydrogen, C1-6alkyl, C2-6alkenyl, and C2-6alkynyl, wherein each C1-6alkyl, C2-6alkenyl, and C2-6alkynyl is optionally substituted with one or more groups independently selected from the group consisting of oxo, halo, amino, hydroxy, and C1-6alkoxy; or two Rc are taken together with the nitrogen to which they are attached to form a heterocyclyl that is optionally substituted with one or more groups independently selected from the group consisting of oxo, halo and C1-3alkyl that is optionally substituted with one or more groups independently selected from the group consisting of oxo and halo;
provided that when:
X is S(O)2;
R1 is an optionally substituted piperazin-1-yl; and
R2—R5 are each H;
then R6 is not: 2,5-dimethoxyphenyl, 3,4-dimethylphenyl, 4-ethylphenyl, 4-bromophenyl, 2,4-dimethylphenyl, 4-ethoxyphenyl, 4-chloro-2-methoxyphenyl, 4-propylphenyl, 2-(trifluoromethyl)phenyl, 2,4,5-trimethylphenyl, 3-methylphenyl, 2-(methylcarbonylamino)-5-methylphenyl, 4-chlorophenyl, 4-(i sopropyl)phenyl, 3-chloro-4-fluorophenyl, 4-cyclohexylphenyl, 4-(isobutyl)phenyl, 2-methylphenyl, 4-acetylphenyl, 4-(tert-butyl)phenyl, 4-(methylcarbonylamino) phenyl, 2-fluorophenyl, phenyl, 3,5-dimethylphenyl, 4-methylphenyl, 5-fluoro-2-methylphenyl, 4-fluorophenyl, 5,6,7,8-tetrahydronaphthlene-2-yl, 2,4,6-trimethylphenyl, 3-chloro-4-fluorophenyl, 4-(ethoxycarbonylamino)phenyl, 2,5-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-methoxyphenyl, 2-methoxy-4-chlorophenyl, or
and provided that when:
X is S(O)2;
R1 is 4-benzylpiperidino; and
R2—R5 are each H;
then R6 is not 4-methylphenyl
and provided that when:
X is C(═O);
R1 is an optionally substituted piperazin-1-yl; and
R2—R5 are each H;
then R6 is not: 2-methoxyphenyl, 2-methylphenyl, 2-chlorophenyl, 4-ethylphenyl, 3,5-dimethylphenyl, 2,3-dimethoxyphenyl, 4-methylphenyl, 4-ethoxyphenyl, 3,4-dimethylphenyl, 2,3-benzodioxazol-5-yl, 3-chlorophenyl, 3-methylphenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl, 2-fluorophenyl, 4-fluorophenyl, 3-fluoro-4-methylphenyl, 2,3-dimethoxyphenyl, 4-(tert-butyl)phenyl, 3,4,5-trimethoxyphenyl, 2-bromophenyl, 4-chlorophenyl, 2-trifluoromethylphenyl, phenyl, 4-bromophenyl, 3,4-difluorophenyl, 2,6-difluorophenyl, 2-(dimethylamino)phenyl, 4-ethoxyphenyl, 3-fluoro-4-methylphenyl, 2,4-dimethylphenyl, 4-(trifluoromethyl)phenyl, 4-(dimethylamino)phenyl, 3-methoxyphenyl, 2-methoxy-4-chloro, or 3-(dimethylamino)phenyl.

### Claim 2 (depends on 1)

The compound of claim 1 which is a compound of formula (Ia):
or a salt thereof.

### Claim 3 (depends on 2)

The compound of claim 2 wherein:
R2 and R3 are each H or wherein R2 and R3 taken together with the carbon to which they are attached form a 5-membered carbocyclic ring ; and
R4 and R5 are each H.

### Claim 4 (depends on 2)

The compound of claim 2 provided that:
when R6 is an optionally substituted phenyl or has the formula:
and
R2—R5 are each H;
then R1 is not 4-benzylpiperidino or piperazin-1-yl that is substituted at the 4-position with a group selected from the group consisting of, methyl, ethyl, 3-chlorophenyl, 4-fluorophenyl, 2-chlorophenyl, 2-fluorophenyl, 4-methoxyphenyl, and 2-methoxyphenyl.

### Claim 5 (depends on 1)

The compound of claim 1 which is a compound of formula (Ib):
or a salt thereof.

### Claim 6 (depends on 5)

The compound of claim 5 wherein:
R2 and R3 are each H or wherein R2 and R3 taken together with the carbon to which they are attached form a 5-membered carbocyclic ring; and
R4 and R5 are each H.

### Claim 7 (depends on 5)

The compound of claim 5 provided that:
when R6 is an optionally substituted phenyl or 2,3-benzodioxazol-5-yl; and
R2—R5 are each H;
then R1 is not piperazin-1-yl that is substituted at the 4-position with a group selected from the group consisting of methyl, ethyl, 3-chlorophenyl, 2-fluorophenyl, 3-chlorophenyl, and 4-fluorophenyl.

### Claim at position 8

8-11. (canceled)

### Claim 12 (depends on 1)

The compound of claim 1 wherein R1 is selected from the group consisting of N-linked piperazinyl, N-linked piperidine, and N-linked diazabicyclo[3.2.1]octane, wherein le is optionally substituted with one or more groups independently selected from C1-6alkyl, aryl, and C3-8cycloalkyl, wherein any aryl and C3-8cycloalkyl is optionally substituted with one or more groups independently selected from halo and C1-4alkyl, and wherein any C1-6alkyl is optionally substituted with one or more groups independently selected from halo, C1-4alkoxy, and C3-8cycloalkyl.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The compound of claim 1 wherein R1 is selected from the roup consisting of:

### Claim at position 12

15-16. (canceled)

### Claim 17 (depends on 1)

The compound of claim 1 wherein R6 is a 6-10 membered aryl that is optionally substituted with one or more groups independently selected from the group consisting of C1-6alkyl, C2-6alkenyl, C2-6alkynyl, carbocycle, heterocycle, aryl, heteroaryl, halo, —NO2, —N(Rb)2, —CN, —C(O)—N(Rb)2, —S(O)—N(Rb)2, —S(O)2—N(Rb)2, —O—Rb, —S—Rb, —O—C(O)—Rb, —C(O)—Rb, —C(O)—ORb, —S(O)—Rb, —S(O)2—Rb, —N(Rb)—C(O)—Rb, —N(Rb)—S(O)—Rb, —N(Rb)—C(O)—N(Rb)2, and —N(Rb)—S(O)2—Rb; wherein each C1-6alkyl, C2-6alkenyl, C2-6alkynyl, carbocycle, heterocycle, aryl, and heteroaryl is optionally substituted with one or more groups independently selected from the group consisting of halo, —NO2—N(Rb)2, —CN, —C(O)—N(Rb)2, —S(O)—N(Rb)2, —S(O)2—N(Rb)2, —O—Rb, —S—Rb, —O—C(O)—Rb, —C(O)—Rb, —C(O)—ORb, —S(O)—Rb, —S(O)2—Rb, —N(Rb)—C(O)—Rb, —N(Rb)—S(O)—Rb, —N(Rb)—C(O)—N(Rb)2, —N(Rb)—S(O)2—Rb, and C1-6alkyl that is optionally substituted with one or more groups independently selected from halo.

### Claim 18 (depends on 1)

The compound of claim 1 wherein R6 is phenyl that is substituted with phenyl that is optionally substituted with one or more groups independently selected from the group consisting of C1-6alkyl, carbocycle, halo, —CN, —C(O)—N(Rb)2, —O—Rb, —S(O)2—Rb, and —N(Rb)—C(O)—Rb, wherein each C1-6alkyl and carbocycle is optionally substituted with one or more groups independently selected from the group consisting of halo.

### Claim 19 (depends on 1)

The compound of claim 1 wherein R6 is phenyl that is optionally substituted with one or more groups independently selected from the group consisting of C1-6alkyl, carbocycle, halo, —CN, —C(O)—N(Rb)2, —O—Rb, —S(O)2—Rb, —N(Rb)—C(O)—Rb, and —N(Rb)—C(O)—N(Rb)2, wherein each C1-6alkyl and carbocycle is optionally substituted with one or more groups independently selected from the group consisting of halo.

### Claim 20 (depends on 1)

The compound of claim lany onc of claims 1 wherein R6 is selected from the group consisting of:

### Claim 21 (depends on 1)

The compound of claim 1 wherein R6 is selected from the group consisting of:

### Claim at position 18

22-27. (canceled)

### Claim 28 (depends on 1)

The compound of claim 1 which is selected from:
or a salt thereof.

### Claim 29

A composition comprising a compound as described in claim, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, carrier, or vehicle.

### Claim 30 (depends on 1)

A method of treating cancer in a mammal in need thereof, comprising administering to the mammal, an effective amount of a compound as described in claim 1, or a pharmaceutically acceptable salt thereof; or a compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
X is C(═O) or S(O)2;
R1 is selected from the group consisting of N-linked piperazinyl, N-linked piperidine, and N-linked diazabicyclo[3.2.1]octane, wherein R1 is optionally substituted with one or more groups independently selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, aryl, 3-10 membered heterocycle, and C3-8cycloalkyl, wherein any aryl, 3-10 membered heterocycle, and C3-8cycloalkyl is optionally substituted with one or more groups independently selected from halo, C1-4alkyl, C2-4alkenyl, and C2-4alkynyl, and wherein any C1-6alkyl, C2-6alkenyl, and C2-6alkynyl is optionally substituted with one or more groups independently selected from halo, C1-4alkoxy, and C3-8cycloalkyl that is optionally substituted with C1-6alkyl;
R2 and R3 are each independently selected from H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, and C3-8cycloalkyl, wherein any C1-6alkyl, C2-6alkenyl, C2-6alkynyl, and C3-8cycloalkyl is optionally substituted with one or more groups independently selected from halo and oxo; or R2 and R3 taken together with the carbon to which they are attached form a 3-, 4-, 5-, or 6-membered carbocyclic ring that is optionally substituted with one or more groups independently selected from halo, oxo, C1-4alkyl, C2-4alkenyl, and C2-4alkynyl;
R4 and R5 are each independently selected from H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, and C3-8cycloalkyl, wherein any C1-6alkyl, C2-6alkenyl, C2-6alkynyl, and C3-8cycloalkyl is optionally substituted with one or more groups independently selected from halo and oxo; or R4 and R5 taken together with the carbon to which they are attached form a 3-, 4-, 5-, or 6-membered carbocyclic ring that is optionally substituted with one or more groups independently selected from halo, oxo, C1-4alkyl, C2-4alkenyl, and C2-4alkynyl;
R6 is a 5-10 membered heteroaryl, 5-10 membered heterocycle, or a 6-10 membered aryl, which 5-10 membered heteroaryl, 5-10 membered heterocycle, and 6-10 membered aryl is optionally substituted with one or more groups independently selected from the group consisting of C1-6alkyl, C2-6alkenyl, C2-6alkynyl, carbocycle, heterocycle, aryl, heteroaryl, halo, —NO2, —N(Rb)2, —CN, —C(O)—N(Rb)2, —S(O)—N(Rb)2, —S(O)2—N(Rb)2, —O—Rb, —S—Rb, —O—C(O)—Rb, —C(O)—Rb, —C(O)—ORb, —S(O)—Rb, —S(O)2—Rb, —N(Rb)—C(O)—Rb, —N(Rb)—S(O)—Rb, —N(Rb)—C(O)—N(Rb)2, and —N(Rb)—S(O)2—Rb; wherein each C1-6alkyl, C2-6alkenyl, C2-6alkynyl, carbocycle, heterocycle, aryl, and heteroaryl is optionally substituted with one or more groups independently selected from the group consisting of halo, —NO2—N(Rb)2, —CN, —C(O)—N(Rb)2, —S(O)—N(Rb)2, —S(O)2—N(Rb)2, —O—Rb, —S—Rb, —O—C(O)—Rb, —C(O)—Rb, —C(O)—ORb, —S(O)—Rb, —S(O)2—Rb, —N(Rb)—C(O)—Rb, —N(Rb)—S(O)—Rb, —N(Rb)—C(O)—N(Rb)2, —N(Rb)—S(O)2—Rb, and C1-6alkyl that is optionally substituted with one or more groups independently selected from halo;
each Rb is independently selected from the group consisting of hydrogen, C1-6alkyl, C2-6alkenyl, aryl, and C2-6alkynyl, wherein each C2-6alkyl, C2-6alkenyl, aryl, and C2-6alkynyl is optionally substituted with one or more groups independently selected from the group consisting of halo, —N(Rc)2, —CN, —C(O)—N(Rc)2, —S(O)—N(Rc)2, —S(O)2—N(Rc)2, —S—Rc, —O—C(O)—Rc, —C(O)—Rc, —C(O)—ORc, —S(O)—Rc, —S(O)2—Rc, —N(Rc)—C(O)—Rc, —N(Rc)—S(O)—Rc, —N(Rc)—C(O)—N(Rc)2, and —N(Rc)—S(O)2—Rc; or two Rb are taken together with the nitrogen to which they are attached to form a pyrrolidino, piperidino, or piperazino ring; and
each RC is independently selected from the group consisting of hydrogen, C1-6alkyl, C2-6alkenyl, and C2-6alkynyl, wherein each C2-6alkyl, C2-6alkenyl, and C2-6alkynyl is optionally substituted with one or more groups independently selected from the group consisting of oxo, halo, amino, hydroxy, and C2-6alkoxy; or two Rcare taken together with the nitrogen to which they are attached to form a heterocyclyl that is optionally substituted with one or more groups independently selected from the group consisting of oxo, halo and C1-3alkyl that is optionally substituted with one or more groups independently selected from the group consisting of oxo and halo.

### Claim 31

(canceled)

### Claim 32 (depends on 1)

A method of inducing differentiation of a cancer stem/progenitor cell(s) in a mammal in need thereof, comprising administering to the mammal, an effective amount of a compound as described in claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 33 (depends on 1)

A method of reducing activity of a cancer stem/progenitor cell(s) in a mammal in need thereof, comprising administering to the mammal, an effective amount of a compound as described in claim lany one of claims 1, or a pharmaceutically acceptable salt thereof.

### Claim 34 (depends on 1)

A method of depleting a cancer stem/progenitor cell in a mammal in need thereof, comprising administering to the mammal, an effective amount of a compound as described in claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 35 (depends on 1)

A method of decreasing cancer initiation in a mammal in need thereof, comprising administering to the mammal, an effective amount of a compound as described in claim 1, or a pharmaceutically acceptable salt thereof.

### Claim at position 27

36-51. (canceled)

### Claim 52

A method of treating cancer in an individual in need thereof, comprising administering an effective amount of a KDM2 inhibitor to the individual.

### Claim at position 29

53-55. (canceled)

### Claim 56

A method of inducing differentiation of a cancer stem/progenitor cell(s) in an individual in need thereof, comprising administering an effective amount of a KDM2 inhibitor to the individual.

### Claim 57

A method of reducing activity of a cancer stem/progenitor cell(s) in an individual in need thereof, comprising administering an effective amount of a KDM2 inhibitor to the individual.

### Claim 58

A method of depleting a cancer stem/progenitor cell population in an individual in need thereof, comprising administering an effective amount of a KDM2 inhibitor to the individual.

### Claim 59

A method of decreasing cancer initiation in an individual in need thereof, comprising administering an effective amount of a KDM2 inhibitor to the individual.

### Claim at position 34

60-62. (canceled)
